

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.9331 — Danaher/GE Healthcare Life Sciences Biopharma

SECTION 1.2

Description of the concentration

- (1) The concentration concerns the acquisition of sole control by Danaher Corporation (“Danaher”) over the GE Healthcare Life Sciences Biopharma Business (“GE Biopharma”) of General Electric Company (“GE”) by means of an acquisition of equity and assets.
- (2) Danaher is the ultimate holding company of a corporate group that designs, manufactures and markets professional, medical, industrial, and commercial products and services.
- (3) GE Biopharma is part of GE’s Healthcare Life Sciences business unit. GE Biopharma supplies instruments, consumables, and software that support the research, discovery, process development and manufacturing workflows of biopharmaceutical drugs, such as monoclonal antibodies, vaccines, and cell and gene therapies.